Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
or

Arcutis Biotherapeutics Inc (ARQT)

Arcutis Biotherapeutics Inc (ARQT)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
13.02 -0.40 (-2.98%) 02/21/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 13.02 unch (unch) 17:02 ET
Quote Overview for Fri, Feb 21st, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
12.75
Day High
13.94
Open 13.62
Previous Close 13.42 13.42
Volume 1,887,100 1,887,100
Avg Vol 2,293,395 2,293,395
Stochastic %K 72.12% 72.12%
Weighted Alpha +23.46 +23.46
5-Day Change +0.71 (+5.77%) +0.71 (+5.77%)
52-Week Range 6.99 - 16.20 6.99 - 16.20
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,523,926
  • Shares Outstanding, K 117,045
  • Annual Sales, $ 59,610 K
  • Annual Income, $ -262,140 K
  • EBIT $ -182 M
  • EBITDA $ -187 M
  • 60-Month Beta 1.29
  • Price/Sales 10.98
  • Price/Cash Flow N/A
  • Price/Book 10.01

Options Overview Details

View History
  • Implied Volatility 97.77% ( +7.29%)
  • Historical Volatility 76.07%
  • IV Percentile 61%
  • IV Rank 38.30%
  • IV High 177.18% on 07/18/24
  • IV Low 48.49% on 10/09/24
  • Put/Call Vol Ratio 1.27
  • Today's Volume 1,904
  • Volume Avg (30-Day) 956
  • Put/Call OI Ratio 0.79
  • Today's Open Interest 29,153
  • Open Int (30-Day) 23,649

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.27
  • Number of Estimates 4
  • High Estimate -0.19
  • Low Estimate -0.33
  • Prior Year -0.72
  • Growth Rate Est. (year over year) +62.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
11.13 +16.98%
on 02/11/25
Period Open: 13.08
15.09 -13.72%
on 01/27/25
-0.06 (-0.46%)
since 01/21/25
3-Month
10.05 +29.55%
on 11/22/24
Period Open: 10.24
16.20 -19.63%
on 01/07/25
+2.78 (+27.15%)
since 11/21/24
52-Week
6.99 +86.27%
on 06/10/24
Period Open: 9.27
16.20 -19.63%
on 01/07/25
+3.75 (+40.45%)
since 02/21/24

Most Recent Stories

More News
Arcutis to Present at the TD Cowen 45th Annual Health Care Conference

ARQT : 13.02 (-2.98%)
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ARQT : 13.02 (-2.98%)
Arcutis to Present at the Guggenheim SMID Cap Biotech Conference

ARQT : 13.02 (-2.98%)
Arcutis Announces Preliminary Unaudited Fourth Quarter Product Revenue and Full-Year 2024 Product Revenues of Approximately $63 Million and $160 Million

ARQT : 13.02 (-2.98%)
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ARQT : 13.02 (-2.98%)
Here's Why Arcutis Stock More Than Doubled in Market Value in One Year

Shares of small biotech Arcutis Biotherapeutics ARQT have surged nearly three times in market value in the past year.The upside has been primarily driven by the positive regulatory updates regarding the...

CTMX : 0.7800 (-4.42%)
CSTL : 25.75 (-1.53%)
ARQT : 13.02 (-2.98%)
SPRO : 0.8310 (-0.68%)
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024

The drug and biotech sector had a turbulent year in 2024, starting strong but losing momentum in the second half. This slowdown was primarily due to disappointing third-quarter earnings, reduced guidance...

MESO : 16.37 (-4.99%)
KOD : 4.45 (-6.12%)
MNPR : 40.25 (-1.76%)
ARQT : 13.02 (-2.98%)
Arcutis Submits ZORYVE® (roflumilast) Cream 0.05% Supplemental New Drug Application to the FDA for the Treatment of Children Aged 2 to 5 with Mild to Moderate Atopic Dermatitis

ARQT : 13.02 (-2.98%)
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ARQT : 13.02 (-2.98%)
Arcutis Announces Promotions on Executive Management Team

ARQT : 13.02 (-2.98%)
Arcutis’ ZORYVE® (roflumilast) Awarded Best Eczema Treatment by Glamour

ARQT : 13.02 (-2.98%)
Arcutis Announces Third Quarter 2024 Financial Results and Provides Business Update

ARQT : 13.02 (-2.98%)
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ARQT : 13.02 (-2.98%)
Arcutis Presents Positive Patient-Reported Outcome Data for ZORYVE® (Roflumilast) Cream 0.15% in Atopic Dermatitis at American College of Allergy, Asthma and Immunology 2024 Annual Scientific Meeting

ARQT : 13.02 (-2.98%)
Arcutis to Report Third Quarter 2024 Financial Results and Participate in an Upcoming Investor Conference

ARQT : 13.02 (-2.98%)
Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older

ARQT : 13.02 (-2.98%)
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ARQT : 13.02 (-2.98%)
3 'Strong-Buy'-Rated Russell 2000 Stocks With 54% to 110% Upside

Investing in these small caps could be rewarding in the long run.

VKTX : 34.07 (+7.71%)
ARQT : 13.02 (-2.98%)
LBPH : 59.98 (+0.03%)
$SPX : 6,013.13 (-1.71%)
5 Breakout Biotech Stocks Leading the Russell 2000 Higher

These small-cap biotech stocks are rallying hard in 2024, and still have room to keep leading the RUT higher.

JANX : 36.01 (-3.12%)
VKTX : 34.07 (+7.71%)
LBPH : 59.98 (+0.03%)
ARQT : 13.02 (-2.98%)
RNA : 31.12 (-4.33%)
S&P Futures Higher After April CPI is Released

June S&P 500 E-Mini futures (ESM24) are trending up +0.45% this morning after April's CPI report was released.

ESM24 : 5,471.89s (-0.09%)
SMCI : 56.07 (-5.40%)
ORCL : 167.81 (-4.65%)
SCHW : 80.44 (-1.70%)
PARA : 11.49 (+0.17%)
CSCO : 63.98 (-1.07%)
GRAB : 4.90 (+2.40%)
MNDY : 300.65 (-2.39%)
EXPN.LN : 3,837.000 (-0.16%)
MRK.D.DX : 135.475 (-0.79%)
NESTE.H.DX : 8.974 (-0.73%)
ARQT : 13.02 (-2.98%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Arcutis Biotherapeutics Inc. is late-stage biopharmaceutical company. It is focused on developing and commercializing treatments for unmet needs in immune-mediated dermatological diseases. The company's product pipeline consists of ARQ-151, ARQ-154 and ARQ-252 for multiple indications, including psoriasis,...

See More

Key Turning Points

3rd Resistance Point 14.91
2nd Resistance Point 14.43
1st Resistance Point 13.72
Last Price 13.02
1st Support Level 12.53
2nd Support Level 12.05
3rd Support Level 11.34

See More

52-Week High 16.20
Last Price 13.02
Fibonacci 61.8% 12.68
Fibonacci 50% 11.60
Fibonacci 38.2% 10.51
52-Week Low 6.99

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

Mastering Fibonacci: The Hidden Order in Market Movements